Selecta Biosciences partners with AskBio to lead the next generation of gene therapy treatments

Selecta Biosciences CombinesImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platformin Strategic Partnership


Selecta Biosciences, Inc.(NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced a strategic partnership to jointly develop, manufacture and commercialize targeted therapeutics for life-changing, next-generation adeno-associated virus (AAV)gene therapiesin areas of high medical need. This partnership will leverage the unique proprietary technology platforms of both companies with a human proof of concept trial to validate thepotential for re-dosing in patientswith genetic diseases.